Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir in Kidney Transplant Recipients with HCV
NCT02251717Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ledipasvir in hepatitis C (HCV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event. Started Oct 2014; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02251717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251717.